OTCMKTS:OPHLF

Ono Pharmaceutical Stock Forecast, Price & News

$22.50
0.00 (0.00 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.50
$22.50
50-Day Range
$22.50
$22.50
52-Week Range
$21.50
$31.00
VolumeN/A
Average Volume1,880 shs
Market Capitalization$11.57 billion
P/E Ratio15.31
Dividend YieldN/A
Beta0.33
30 days | 90 days | 365 days | Advanced Chart
Receive OPHLF News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


Ono Pharmaceutical logo

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Headlines

Heres what to expect from Ono Pharmaceuticals earnings
Here's what to expect from Ono Pharmaceutical's earnings
January 31, 2021 |  markets.businessinsider.com
News for Ono Pharmaceutical
News for Ono Pharmaceutical
December 26, 2020 |  markets.businessinsider.com
Fate Therapeutics Jumped On Supportive Trial Data
Fate Therapeutics Jumped On Supportive Trial Data
December 18, 2020 |  seekingalpha.com
Gileads Cancer Follies
Gilead's Cancer Follies
October 2, 2020 |  seekingalpha.com
Ono Pharmaceutical Co., Ltd. (OPHLF)
Ono Pharmaceutical Co., Ltd. (OPHLF)
August 16, 2020 |  ca.finance.yahoo.com
Ono Pharmaceutical Co Ltd (Japan) (OPHLF)
Ono Pharmaceutical Co Ltd (Japan) (OPHLF)
August 2, 2020 |  www.nasdaq.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.30 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ono Pharmaceutical (OTCMKTS:OPHLF) Frequently Asked Questions

What stocks does MarketBeat like better than Ono Pharmaceutical?

Wall Street analysts have given Ono Pharmaceutical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ono Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 84,800 shares, a decline of 40.2% from the August 15th total of 141,700 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
View Ono Pharmaceutical's Short Interest
.

When is Ono Pharmaceutical's next earnings date?

Ono Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Ono Pharmaceutical
.

How has Ono Pharmaceutical's stock price been impacted by Coronavirus?

Ono Pharmaceutical's stock was trading at $22.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPHLF shares have increased by 2.3% and is now trading at $22.50.
View which stocks have been most impacted by COVID-19
.

Who are Ono Pharmaceutical's key executives?

Ono Pharmaceutical's management team includes the following people:
  • Mr. Gyo Sagara, CEO, Pres & Representative Director
  • Mr. Shozo Matsuoka, Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
  • Yukio Tani, Corp. Exec. Officer & Head of Corp. Communications
  • Mr. Hiroshi Ichikawa, Corp. Sr. Exec. Officer and Exec. Director of Sales & Marketing
  • Mr. Isao Ono, Exec. Officer, Director of Corp. Research & Director
  • Mr. Hiroshi Awata, VP, Exec. Officer, Tokyo Branch Head & Director
  • Mr. Toichi Takino, Exec. Officer, Exec. Director of Discovery & Research and Director
  • Takuya Seko, Corp. Officer & Chief Officer of Quality Assurance Management
  • Mr. Toshihiro Tsujinaka, Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director
  • Kiyoaki Idemitsu, Corp. Exec. Officer & Exec. Director of Clinical Devel.

Who are some of Ono Pharmaceutical's key competitors?

What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ono Pharmaceutical's stock price today?

One share of OPHLF stock can currently be purchased for approximately $22.50.

How much money does Ono Pharmaceutical make?

Ono Pharmaceutical has a market capitalization of $11.57 billion and generates $2.92 billion in revenue each year. The company earns $708.99 million in net income (profit) each year or $1.43 on an earnings per share basis.

How many employees does Ono Pharmaceutical have?

Ono Pharmaceutical employs 3,607 workers across the globe.

What is Ono Pharmaceutical's official website?

The official website for Ono Pharmaceutical is www.ono.co.jp.

Where are Ono Pharmaceutical's headquarters?

Ono Pharmaceutical is headquartered at 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564.

How can I contact Ono Pharmaceutical?

Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The company can be reached via phone at 816-6263-5670.


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.